<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047110</url>
  </required_header>
  <id_info>
    <org_study_id>1311.8</org_study_id>
    <secondary_id>2013-003666-13</secondary_id>
    <nct_id>NCT02047110</nct_id>
  </id_info>
  <brief_title>BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)</brief_title>
  <official_title>A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <brief_summary>
    <textblock>
      The overall purpose of the trial is to assess the clinical efficacy of three different
      subcutaneous doses of BI 655066 (risankizumab) in adult patients with AS, in order to provide
      clinical proof of concept and to select dose (s) for confirmatory clinical trials.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2014</start_date>
  <completion_date type="Actual">July 25, 2016</completion_date>
  <primary_completion_date type="Actual">March 5, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients Who Achieved Assessment of Spondyloarthritis International Society (ASAS) 40 Improvement Criteria at Week 12.</measure>
    <time_frame>Week 12</time_frame>
    <description>ASAS 40 evaluations are based on the following 4 components (also called domains) that include patient' self-assessments on a numerical rating scale (NRS) from 0 to 10 with higher numbers representing a worse disease status:
Global AS disease activity
Inflammation based on the mean of Bath AS Disease Activity Index (BASDAI) questions addressing the level of morning stiffness and duration
Spinal pain based on the mean of 2 questions
Physical function based on the Bath AS Functional Index (BASFI) The ASAS 40 response is defined as an improvement in 3 of 4 components and no worsening in the remaining component; an improvement is defined as a reduction from baseline of ≥40% and an absolute reduction of ≥2 units in each of the 3 components.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Disease Activity Assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS).</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>This is the key secondary endpoint. ASDAS is a linear function of Back Pain (Question 2 from Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI): range 0-10), Duration of Morning Stiffness (Question 6 from BASDAI: range 0-10), Patient's global assessment of the disease on Numerical rating Scale (NRS) (range 0-10), peripheral joint pain/swelling (Question 3 from BASDAI: range 0-10) and the C-reactive protein (CRP) lab value at the visit. ASDAS-CRP: 0.121*Back pain +0.058*Duration of Morning Stiffness +0.11*Patient Global + 0.073*Peripheral pain/ Swelling + 0.579*Ln (CRP +1). For all of the scales that make up the ASDAS, higher indicates worse disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved ASAS 5/6 Improvement Criteria at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The ASAS 5/6 evaluation is based on 6 components:
Global AS disease activity
Inflammation based on the mean of BASDAI questions addressing the level-of morning stiffness and duration
Spinal pain
Physical function based on the Bath AS Functional Index (BASFI)
Spinal mobility assessment (lateral lumbar flexion), corresponding to one out of 5 measurements of Bath Ankylosing Spondylitis Metrology Index (BASMI)
Serum CRP levels The ASAS 5/6 response is defined as an improvement in any 5 of the 6 components and no worsening in the remaining component. A reduction from baseline of ≥20% is defined as an improvement according to the ASAS criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved Partial Remission According to the ASAS Criteria at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Percentage of patients who achieved partial remission according to the ASAS criteria at Week 12 is presented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved ASAS 20 Improvement Criteria at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>ASAS 20 evaluations are based on the following 4 components (also called domains) that include patient' self-assessments on a numerical rating scale (NRS) from 0 to 10 with higher numbers representing a worse disease status:
Global AS disease activity
Inflammation based on the mean of Bath AS Disease Activity Index (BASDAI) questions addressing the level of morning stiffness and duration
Spinal pain based on the mean of 2 questions
Physical function based on the Bath AS Functional Index (BASFI) The ASAS 20 response is defined as an improvement in 3 of 4 components and no worsening in the remaining component; an improvement is defined as a reduction from baseline of ≥20% and an absolute reduction of ≥1 units in each of the 3 components.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Disease Activity Assessed by BASDAI</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>BASDAI assesses the AS disease activity of a patient within the last week based on 6 questions on a NRS (1 to 10) How would you describe the overall level of
fatigue/tiredness you have experienced?
AS neck, back or hip pain you have had?
pain/swelling in joints other than neck, back or hips you have had?
discomfort you have had from any areas tender to touch or pressure?
morning stiffness you have had from the time you wake up? How long does your
morning stiffness last from the time you wake up?
A score of 10 means very severe disease activity for each of the BASDAI questions 1, 2, 3, 4 and 5. BASDAI question 6 addresses the stiffness duration. A NRS of 0 means 0 h; a NRS of 10 mean ≥2 h.
The BASDAI was computed in the following way: the sum of the values of question 1 to 4 was calculated and the mean of questions 5 and 6 was added. This value was divided by 5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Achieved ASAS 40 Improvement Criteria at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of patients who achieved ASAS 40 improvement criteria at Week 24 is presented</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Ankylosing Spondylitis (AS)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab 18 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab 90 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risankizumab 180 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for risankizumab</intervention_name>
    <description>Placebo for risankizumab administered by subcutaneous (SC) injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>risankizumab</intervention_name>
    <description>Risankizumab administered by subcutaneous (SC) injection</description>
    <arm_group_label>Risankizumab 18 mg</arm_group_label>
    <arm_group_label>Risankizumab 180 mg</arm_group_label>
    <arm_group_label>Risankizumab 90 mg</arm_group_label>
    <other_name>ABBV-066</other_name>
    <other_name>BI 655066</other_name>
    <other_name>SKYRIZI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female patients

          2. Age = 18 years and = 70 years

          3. Definite AS based on the modified New York criteria (1984)

          4. Documented disease duration = 3 months at screening

          5. Active disease at screening, defined as:

               1. BASDAI score (0-10) = 4, AND

               2. Spinal pain level assessed by the 2nd BASDAI question (0-10) = 4

          6. Have either a documented inadequate response for axial symptoms to 30 days of optimal
             daily doses of at least two non-steroidal anti-inflammatory drugs (NSAIDs), or
             documented intolerance to NSAIDs

          7. Female patients who meet any of the following criteria from screening visit up to the
             End of Observation visit (EOO):

               -  using adequate contraception, e.g. any of the following methods plus condom:
                  implants, injectables, combined oral contraceptives, intrauterine device (IUD)

               -  sexually abstinent

               -  have a vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)

               -  surgically sterilised (including hysterectomy)

               -  postmenopausal defined as at least 1 year of spontaneous Amenorrhea

          8. Patients (males or females) receiving background MTX or Leflunomide therapy who are
             following the national regulatory guidelines regarding contraception

          9. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and local legislation

        Exclusion criteria:

          1. Radiographic evidence of total ankylosis of the spine at screening or before (spinal
             XRay examinations at screening visit/ during screening period are not mandatory ¿ see
             footnote 12 from Flow-Chart 1)

          2. Patient previously treated with any biological immunomodulating agent for AS, either
             licensed or experimental

          3. Previous or current participation in a clinical trial testing an investigational drug
             for AS within 12 weeks prior to randomization (any biological immunomodulating agents
             are excluded)

          4. Usage of any investigational drug within 30 days prior to randomization or the planned
             use of an investigational drug during the course of the actual study

          5. Active uveitis or inflammatory bowel disease at screening

          6. Diagnosed psoriatic arthritis at screening, satisfying the modified New York criteria

          7. Patients who had received intraarticular injection(s) with corticosteroids within 4
             weeks prior to screening visit

          8. Patients who must or wish to continue the intake of restricted medications (cf.
             Section 4.2.2.1) or any drug considered likely to interfere with the safe conduct of
             the study

          9. Major surgery performed within 8 weeks prior to screening or planned within 12 months
             after screening (e.g. hip replacement)

         10. Chronic or relevant acute infections including HIV, viral hepatitis and tuberculosis
             (positive tests for HIV, HBV/HCV at screening will be exclusionary)

             For tuberculosis patients, they are not eligible according to the following screening
             criteria:

               -  Have signs or symptoms suggestive of current active or latent TB upon medical
                  history, physical examination and/or a chest radiograph (both posterior-anterior
                  and lateral views, taken within 3 months prior to the first administration of
                  study drug and read by a qualified radiologist)

               -  Have history of latent or active TB prior to screening, except for patients who
                  have documentation of having completed an adequate treatment regimen at least 6
                  months prior to the first administration of study agent

               -  Have positive QuantiFERON-TB Gold In-Tube test within 2 months prior to or during
                  screening, in which active TB has not been ruled out, except for patients with
                  history of latent TB and documentation of having completed an adequate treatment
                  regimen at least 6 months prior to the first administration of study agent

         11. Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal cell carcinoma of the skin or
             in situ carcinoma of uterine cervix

         12. Evidence of current or previous clinically significant disease, medical condition
             other than AS, finding of the medical examination (including vital signs and ECG), or
             laboratory value at the screening visit outside the reference range that is of
             clinical relevance, that in the opinion of the Investigator, would compromise the
             safety of the patient or the quality of the data. This criterion provides an
             opportunity for the investigator to exclude patients based on clinical judgment, even
             if other eligibility criteria are satisfied.

         13. History of allergy/hypersensitivity to a systemically administered biologic agent or
             its excipients

         14. History of alcohol abuse within last 12 months (intake of more than 30 g/day)

         15. History of drug abuse within last 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <results_first_submitted>May 3, 2019</results_first_submitted>
  <results_first_submitted_qc>May 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 31, 2019</results_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The trial had a double blind (DB) treatment period up to Week 24, an Escape treatment period up to Week 40, and an open-label-extension (OLE) treatment period that lasted 26 weeks after OLE entry. Each of the treatment periods was followed by a 24- week post-treatment follow-up period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
        </group>
        <group group_id="P2">
          <title>Risankizumab 18 mg</title>
          <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Risankizumab 90 mg</title>
          <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
        </group>
        <group group_id="P4">
          <title>Risankizumab 180 mg</title>
          <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>DB Treatment Period up to Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40">Started are the treated patients</participants>
                <participants group_id="P2" count="40">Started are the treated patients</participants>
                <participants group_id="P3" count="39">Started are the treated patients</participants>
                <participants group_id="P4" count="40">Started are the treated patients</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>DB (Week 12 up to Week 24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9">Patients who continued treatment in the DB treatment period up to Week 24</participants>
                <participants group_id="P2" count="17">Patients who continued treatment in the DB treatment period up to Week 24</participants>
                <participants group_id="P3" count="13">Patients who continued treatment in the DB treatment period up to Week 24</participants>
                <participants group_id="P4" count="12">Patients who continued treatment in the DB treatment period up to Week 24</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Escape Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">Assessment in SpondyloArthritis international Society (ASAS) 20 nonresponders</participants>
                <participants group_id="P2" count="21">ASAS 20 nonresponders</participants>
                <participants group_id="P3" count="23">ASAS 20 nonresponders</participants>
                <participants group_id="P4" count="26">ASAS 20 nonresponders</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>OLE Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">Patients with loss of ASAS 20 response compared with baseline</participants>
                <participants group_id="P2" count="8">Patients with loss of ASAS 20 response compared with baseline</participants>
                <participants group_id="P3" count="5">Patients with loss of ASAS 20 response compared with baseline</participants>
                <participants group_id="P4" count="9">Patients with loss of ASAS 20 response compared with baseline</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): All patients who received at least 1 dose of trial medication</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
        </group>
        <group group_id="B2">
          <title>Risankizumab 18 mg</title>
          <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Risankizumab 90 mg</title>
          <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
        </group>
        <group group_id="B4">
          <title>Risankizumab 180 mg</title>
          <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="39"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.6" spread="11.0"/>
                    <measurement group_id="B2" value="38.0" spread="11.1"/>
                    <measurement group_id="B3" value="39.5" spread="10.8"/>
                    <measurement group_id="B4" value="40.6" spread="11.9"/>
                    <measurement group_id="B5" value="38.9" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients Who Achieved Assessment of Spondyloarthritis International Society (ASAS) 40 Improvement Criteria at Week 12.</title>
        <description>ASAS 40 evaluations are based on the following 4 components (also called domains) that include patient' self-assessments on a numerical rating scale (NRS) from 0 to 10 with higher numbers representing a worse disease status:
Global AS disease activity
Inflammation based on the mean of Bath AS Disease Activity Index (BASDAI) questions addressing the level of morning stiffness and duration
Spinal pain based on the mean of 2 questions
Physical function based on the Bath AS Functional Index (BASFI) The ASAS 40 response is defined as an improvement in 3 of 4 components and no worsening in the remaining component; an improvement is defined as a reduction from baseline of ≥40% and an absolute reduction of ≥2 units in each of the 3 components.</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab 18 mg</title>
            <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Risankizumab 90 mg</title>
            <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
          <group group_id="O4">
            <title>Risankizumab 180 mg</title>
            <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved Assessment of Spondyloarthritis International Society (ASAS) 40 Improvement Criteria at Week 12.</title>
          <description>ASAS 40 evaluations are based on the following 4 components (also called domains) that include patient' self-assessments on a numerical rating scale (NRS) from 0 to 10 with higher numbers representing a worse disease status:
Global AS disease activity
Inflammation based on the mean of Bath AS Disease Activity Index (BASDAI) questions addressing the level of morning stiffness and duration
Spinal pain based on the mean of 2 questions
Physical function based on the Bath AS Functional Index (BASFI) The ASAS 40 response is defined as an improvement in 3 of 4 components and no worsening in the remaining component; an improvement is defined as a reduction from baseline of ≥40% and an absolute reduction of ≥2 units in each of the 3 components.</description>
          <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="20.5"/>
                    <measurement group_id="O4" value="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To control the type I error rate, the primary endpoint was tested in a hierarchical fixed sequence approach. The proportion of patients achieving ASAS 40 response at Week 12 was pairwise compared in the following sequence: risankizumab 180 mg vs. placebo (1.) and risankizumab 90 mg vs. placebo (2.). The significance level was 5% (1-sided). The comparison risankizumab 18 mg vs. placebo was not included in the formal testing sequence; an exploratory p-value was provided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2652</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the primary endpoint, ASAS 40 response at Week 12, between treatment groups.</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>26.6</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper-Pearson method. Difference calculated as &quot;risankizumab 18 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To control the type I error rate, the primary endpoint was tested in a hierarchical fixed sequence approach. The proportion of patients achieving ASAS 40 response at Week 12 was pairwise compared in the following sequence: risankizumab 180 mg vs. placebo (1.) and risankizumab 90 mg vs. placebo (2.). The significance level was 5% (1-sided). The comparison risankizumab 18 mg vs. placebo was not included in the formal testing sequence; an exploratory p-value was provided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4129</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the primary endpoint, ASAS 40 response at Week 12, between treatment groups.</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.9</ci_lower_limit>
            <ci_upper_limit>20.8</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 90 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>To control the type I error rate, the primary endpoint was tested in a hierarchical fixed sequence approach. The proportion of patients achieving ASAS 40 response at Week 12 was pairwise compared in the following sequence: risankizumab 180 mg vs. placebo (1.) and risankizumab 90 mg vs. placebo (2.). The significance level was 5% (1-sided). The comparison risankizumab 18 mg vs. placebo was not included in the formal testing sequence; an exploratory p-value was provided.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4243</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the primary endpoint, ASAS 40 response at Week 12, between treatment groups</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.8</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 180 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Disease Activity Assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS).</title>
        <description>This is the key secondary endpoint. ASDAS is a linear function of Back Pain (Question 2 from Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI): range 0-10), Duration of Morning Stiffness (Question 6 from BASDAI: range 0-10), Patient's global assessment of the disease on Numerical rating Scale (NRS) (range 0-10), peripheral joint pain/swelling (Question 3 from BASDAI: range 0-10) and the C-reactive protein (CRP) lab value at the visit. ASDAS-CRP: 0.121*Back pain +0.058*Duration of Morning Stiffness +0.11*Patient Global + 0.073*Peripheral pain/ Swelling + 0.579*Ln (CRP +1). For all of the scales that make up the ASDAS, higher indicates worse disease.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab 18 mg</title>
            <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Risankizumab 90 mg</title>
            <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
          <group group_id="O4">
            <title>Risankizumab 180 mg</title>
            <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Disease Activity Assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS).</title>
          <description>This is the key secondary endpoint. ASDAS is a linear function of Back Pain (Question 2 from Bath Ankylosing Spondylitis (AS) Disease Activity Index (BASDAI): range 0-10), Duration of Morning Stiffness (Question 6 from BASDAI: range 0-10), Patient's global assessment of the disease on Numerical rating Scale (NRS) (range 0-10), peripheral joint pain/swelling (Question 3 from BASDAI: range 0-10) and the C-reactive protein (CRP) lab value at the visit. ASDAS-CRP: 0.121*Back pain +0.058*Duration of Morning Stiffness +0.11*Patient Global + 0.073*Peripheral pain/ Swelling + 0.579*Ln (CRP +1). For all of the scales that make up the ASDAS, higher indicates worse disease.</description>
          <population>FAS</population>
          <units>Unit on scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.9" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-1.3" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-0.6" lower_limit="-1.0" upper_limit="0.1"/>
                    <measurement group_id="O4" value="-0.7" lower_limit="-1.1" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0229</p_value>
            <p_value_desc>One sided p-value from Wilcoxon rank−sum test</p_value_desc>
            <method>Wilcoxon rank−sum test</method>
            <param_type>Median estimate by Hodges−Lehmann method</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Moses method. Difference calculated as &quot;risankizumab 18 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1038</p_value>
            <p_value_desc>One sided p-value from Wilcoxon rank−sum test</p_value_desc>
            <method>Wilcoxon rank−sum test</method>
            <param_type>Median estimate by Hodges−Lehmann method</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Moses method. Difference calculated as &quot;risankizumab 90 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0101</p_value>
            <p_value_desc>One sided p-value from Wilcoxon rank−sum test</p_value_desc>
            <method>Wilcoxon rank−sum test</method>
            <param_type>Median estimate by Hodges−Lehmann method</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Moses method. Difference calculated as &quot;risankizumab 180 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved ASAS 5/6 Improvement Criteria at Week 12</title>
        <description>The ASAS 5/6 evaluation is based on 6 components:
Global AS disease activity
Inflammation based on the mean of BASDAI questions addressing the level-of morning stiffness and duration
Spinal pain
Physical function based on the Bath AS Functional Index (BASFI)
Spinal mobility assessment (lateral lumbar flexion), corresponding to one out of 5 measurements of Bath Ankylosing Spondylitis Metrology Index (BASMI)
Serum CRP levels The ASAS 5/6 response is defined as an improvement in any 5 of the 6 components and no worsening in the remaining component. A reduction from baseline of ≥20% is defined as an improvement according to the ASAS criteria.</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab 18 mg</title>
            <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Risankizumab 90 mg</title>
            <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
          <group group_id="O4">
            <title>Risankizumab 180 mg</title>
            <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved ASAS 5/6 Improvement Criteria at Week 12</title>
          <description>The ASAS 5/6 evaluation is based on 6 components:
Global AS disease activity
Inflammation based on the mean of BASDAI questions addressing the level-of morning stiffness and duration
Spinal pain
Physical function based on the Bath AS Functional Index (BASFI)
Spinal mobility assessment (lateral lumbar flexion), corresponding to one out of 5 measurements of Bath Ankylosing Spondylitis Metrology Index (BASMI)
Serum CRP levels The ASAS 5/6 response is defined as an improvement in any 5 of the 6 components and no worsening in the remaining component. A reduction from baseline of ≥20% is defined as an improvement according to the ASAS criteria.</description>
          <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0238</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 12, between treatment groups.</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.6</ci_lower_limit>
            <ci_upper_limit>33.8</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper-Pearson method. Difference calculated as &quot;risankizumab 18 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0120</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 12, between treatment groups.</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>35.3</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 90 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0465</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 12, between treatment groups</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>31.4</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 180 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved Partial Remission According to the ASAS Criteria at Week 12</title>
        <description>Percentage of patients who achieved partial remission according to the ASAS criteria at Week 12 is presented</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab 18 mg</title>
            <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Risankizumab 90 mg</title>
            <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
          <group group_id="O4">
            <title>Risankizumab 180 mg</title>
            <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved Partial Remission According to the ASAS Criteria at Week 12</title>
          <description>Percentage of patients who achieved partial remission according to the ASAS criteria at Week 12 is presented</description>
          <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="2.5"/>
                    <measurement group_id="O3" value="2.6"/>
                    <measurement group_id="O4" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>p-values are not presented as they were not meaningful; 3 treatment groups had only a single patient with partial remission.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.4</ci_lower_limit>
            <ci_upper_limit>19.4</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper-Pearson method. Difference calculated as &quot;risankizumab 18 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>p-values are not presented as they were not meaningful; 3 treatment groups had only a single patient with partial remission.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.3</ci_lower_limit>
            <ci_upper_limit>18.3</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 90 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>p-values are not presented as they were not meaningful; 3 treatment groups had only a single patient with partial remission.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>26.6</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 180 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved ASAS 20 Improvement Criteria at Week 12</title>
        <description>ASAS 20 evaluations are based on the following 4 components (also called domains) that include patient' self-assessments on a numerical rating scale (NRS) from 0 to 10 with higher numbers representing a worse disease status:
Global AS disease activity
Inflammation based on the mean of Bath AS Disease Activity Index (BASDAI) questions addressing the level of morning stiffness and duration
Spinal pain based on the mean of 2 questions
Physical function based on the Bath AS Functional Index (BASFI) The ASAS 20 response is defined as an improvement in 3 of 4 components and no worsening in the remaining component; an improvement is defined as a reduction from baseline of ≥20% and an absolute reduction of ≥1 units in each of the 3 components.</description>
        <time_frame>Week 12</time_frame>
        <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab 18 mg</title>
            <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Risankizumab 90 mg</title>
            <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
          <group group_id="O4">
            <title>Risankizumab 180 mg</title>
            <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved ASAS 20 Improvement Criteria at Week 12</title>
          <description>ASAS 20 evaluations are based on the following 4 components (also called domains) that include patient' self-assessments on a numerical rating scale (NRS) from 0 to 10 with higher numbers representing a worse disease status:
Global AS disease activity
Inflammation based on the mean of Bath AS Disease Activity Index (BASDAI) questions addressing the level of morning stiffness and duration
Spinal pain based on the mean of 2 questions
Physical function based on the Bath AS Functional Index (BASFI) The ASAS 20 response is defined as an improvement in 3 of 4 components and no worsening in the remaining component; an improvement is defined as a reduction from baseline of ≥20% and an absolute reduction of ≥1 units in each of the 3 components.</description>
          <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="45.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0092</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 12, between treatment groups.</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>25.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.5</ci_lower_limit>
            <ci_upper_limit>43.1</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper-Pearson method. Difference calculated as &quot;risankizumab 18 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1243</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 12, between treatment groups.</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.9</ci_lower_limit>
            <ci_upper_limit>30.5</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 90 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1198</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 12, between treatment groups</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>31.4</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 180 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Disease Activity Assessed by BASDAI</title>
        <description>BASDAI assesses the AS disease activity of a patient within the last week based on 6 questions on a NRS (1 to 10) How would you describe the overall level of
fatigue/tiredness you have experienced?
AS neck, back or hip pain you have had?
pain/swelling in joints other than neck, back or hips you have had?
discomfort you have had from any areas tender to touch or pressure?
morning stiffness you have had from the time you wake up? How long does your
morning stiffness last from the time you wake up?
A score of 10 means very severe disease activity for each of the BASDAI questions 1, 2, 3, 4 and 5. BASDAI question 6 addresses the stiffness duration. A NRS of 0 means 0 h; a NRS of 10 mean ≥2 h.
The BASDAI was computed in the following way: the sum of the values of question 1 to 4 was calculated and the mean of questions 5 and 6 was added. This value was divided by 5.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab 18 mg</title>
            <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Risankizumab 90 mg</title>
            <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
          <group group_id="O4">
            <title>Risankizumab 180 mg</title>
            <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Disease Activity Assessed by BASDAI</title>
          <description>BASDAI assesses the AS disease activity of a patient within the last week based on 6 questions on a NRS (1 to 10) How would you describe the overall level of
fatigue/tiredness you have experienced?
AS neck, back or hip pain you have had?
pain/swelling in joints other than neck, back or hips you have had?
discomfort you have had from any areas tender to touch or pressure?
morning stiffness you have had from the time you wake up? How long does your
morning stiffness last from the time you wake up?
A score of 10 means very severe disease activity for each of the BASDAI questions 1, 2, 3, 4 and 5. BASDAI question 6 addresses the stiffness duration. A NRS of 0 means 0 h; a NRS of 10 mean ≥2 h.
The BASDAI was computed in the following way: the sum of the values of question 1 to 4 was calculated and the mean of questions 5 and 6 was added. This value was divided by 5.</description>
          <population>FAS</population>
          <units>Unit on scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-2.8" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-2.8" upper_limit="-0.4"/>
                    <measurement group_id="O3" value="-0.8" lower_limit="-2.1" upper_limit="1.0"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-2.0" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1241</p_value>
            <p_value_desc>One sided p-value from Wilcoxon rank−sum test</p_value_desc>
            <method>Wilcoxon rank−sum test</method>
            <param_type>Median estimate by Hodges−Lehmann method</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Moses method. Difference calculated as &quot;risankizumab 18 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3033</p_value>
            <p_value_desc>One sided p-value from Wilcoxon rank−sum test</p_value_desc>
            <method>Wilcoxon rank−sum test</method>
            <param_type>Median estimate by Hodges−Lehmann method</param_type>
            <param_value>0.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Moses method. Difference calculated as &quot;risankizumab 90 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3203</p_value>
            <p_value_desc>One sided p-value from Wilcoxon rank−sum test</p_value_desc>
            <method>Wilcoxon rank−sum test</method>
            <param_type>Median estimate by Hodges−Lehmann method</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.4</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Moses method. Difference calculated as &quot;risankizumab 180 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Achieved ASAS 40 Improvement Criteria at Week 24</title>
        <description>Percentage of patients who achieved ASAS 40 improvement criteria at Week 24 is presented</description>
        <time_frame>Week 24</time_frame>
        <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
          </group>
          <group group_id="O2">
            <title>Risankizumab 18 mg</title>
            <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Risankizumab 90 mg</title>
            <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
          <group group_id="O4">
            <title>Risankizumab 180 mg</title>
            <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Achieved ASAS 40 Improvement Criteria at Week 24</title>
          <description>Percentage of patients who achieved ASAS 40 improvement criteria at Week 24 is presented</description>
          <population>Full Analysis set (FAS): FAS comprised of all randomised patients who received at least 1 dose of trial medication</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0"/>
                    <measurement group_id="O2" value="22.5"/>
                    <measurement group_id="O3" value="23.1"/>
                    <measurement group_id="O4" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2639</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 24, between treatment groups.</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.1</ci_lower_limit>
            <ci_upper_limit>26.6</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper-Pearson method. Difference calculated as &quot;risankizumab 18 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2691</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 24, between treatment groups.</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.9</ci_lower_limit>
            <ci_upper_limit>25.7</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 90 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4174</p_value>
            <p_value_desc>The Suissa-Shuster unconditional exact test was used to test the difference in the proportion of patients achieving the endpoint at Week 24, between treatment groups</p_value_desc>
            <method>Suissa-Shuster unconditional exact test</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.8</ci_lower_limit>
            <ci_upper_limit>17.0</ci_upper_limit>
            <estimate_desc>The confidence interval for the difference in proportion between the treatment groups was obtained by the Clopper- Pearson method. Difference calculated as &quot;risankizumab 180 mg minus Placebo&quot;.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events reported during the DB, the Escape, and the OLE treatment period; up to 50 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subcutaneous injection of Placebo (solution for injection matching risankizumab, 1 mL pre-filled syringe) administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period.</description>
        </group>
        <group group_id="E2">
          <title>Risankizumab 18 mg</title>
          <description>Subcutaneous injection of risankizumab 18 mg administered every 8 weeks at Day 1 only, followed by placebo every 8 weeks (i.e. at Week 8, 16 and 24), up to a total duration of 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Risankizumab 90 mg</title>
          <description>Subcutaneous injection of risankizumab 90 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
        </group>
        <group group_id="E4">
          <title>Risankizumab 180 mg</title>
          <description>Subcutaneous injection of risankizumab 180 mg administered every 8 weeks (At Day1 and at Weeks 8, 16, and 24) up to 4 times during the regular treatment period</description>
        </group>
        <group group_id="E5">
          <title>Escape Low</title>
          <description>Patients who received risankizumab 180 mg in the Escape treatment period and who were randomized to either Placebo or risankizumab 18 mg at Day 1 of the DB treatment period</description>
        </group>
        <group group_id="E6">
          <title>Escape High</title>
          <description>Patients who received risankizumab 180 mg in the Escape treatment period and who were randomized to either risankizumab 90 mg or risankizumab 180 mg at Day 1 of the DB treatment period</description>
        </group>
        <group group_id="E7">
          <title>Escape</title>
          <description>Patients who received escape treatments of risankizumab 180 mg regardless of the initial randomization group</description>
        </group>
        <group group_id="E8">
          <title>Open Label Extension (OLE)</title>
          <description>Patients who received 180 mg risankizumab (administered subcutaneously) every 8 weeks in OLE treatment period</description>
        </group>
        <group group_id="E9">
          <title>Risankizumab High</title>
          <description>Patients who received at least one risankizumab 90 mg or 180 mg treatment during the entire trial</description>
        </group>
        <group group_id="E10">
          <title>Risankizumab Total</title>
          <description>Patients who received at least one risankizumab treatment at any dose level</description>
        </group>
        <group group_id="E11">
          <title>Total_all</title>
          <description>All randomised patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Incision site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="27" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="85" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="91" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="99" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="11" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="30" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="32" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="33" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankylosing spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="17" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The hierarchical testing p-values are exploratory in nature, due to the study design, as the primary endpoint of study failed to meet the desired objective.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

